

BIOLARGO, INC.  
Form 10-Q  
August 14, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

**QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended June 30, 2008.

or

**TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-19709

**BIOLARGO, INC.**

*(Exact name of registrant as specified in its charter)*

Edgar Filing: BIOLARGO, INC. - Form 10-Q

**Delaware** **65-0159115**  
*(State or other jurisdiction of incorporation or organization)* *(I.R.S. Employer Identification No.)*  
**2603 Main Street, Suite 1155, Irvine, California 92614**

*(Address, including zip code, of principal executive offices)*

**(949) 235-8062**

*(Registrant's telephone number, including area code)*

**Securities registered pursuant to Section 12(b) of the Exchange Act: None**

**Securities registered pursuant to Section 12(g) of the Exchange Act: Common Stock, \$0.0067 par value.**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares of the Registrant's Common Stock outstanding as of June 30, 2008 was 40,592,247 shares.

**BIOLARGO, INC.**

**FORM 10-Q**

**INDEX**

**PART I**

Item 1	<u>Financial Statements</u>	1
Item 2	<u>Management's Discussion and Analysis</u>	17
Item 3	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	22
Item 4T	<u>Controls and Procedures</u>	22

**PART II**

Item 1	<u>Legal Proceedings</u>	23
Item 1A	<u>Risk Factors</u>	23
Item 2	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	23
Item 3	<u>Defaults Upon Senior Securities</u>	23
Item 4	<u>Submission of Matters to a Vote of Security Holders</u>	24
Item 5	<u>Other Information</u>	24
Item 6	<u>Exhibits</u>	24
	<u>Signatures</u>	24
	<u>Exhibit Index</u>	25
	Exhibit 31.1	
	Exhibit 31.2	
	Exhibit 32	

## PART I

## Item 1. Financial Statements

## BIOLARGO, INC. AND SUBSIDIARY

## CONSOLIDATED BALANCE SHEETS

AS OF DECEMBER 31, 2007 AND JUNE 30, 2008

	December 31, 2007	June 30, 2008 (unaudited)
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$ 457,809	\$ 614,478
Prepaid expenses	4,584	4,586
Total current assets	462,393	619,064
<b>FIXED ASSETS</b>		
Equipment		16,414
Total fixed assets		16,414
<b>OTHER ASSETS</b>		
Licensing rights, net	10,655,164	10,144,108
Assigned agreements, net	340,377	297,831
<b>TOTAL ASSETS</b>	<b>\$ 11,457,934</b>	<b>\$ 11,077,417</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable and accrued expenses	\$ 781,221	\$ 968,951
Accrued option compensation expense	635,845	593,520
Convertible notes payable, current portion	1,000,000	1,925,000
Discount on convertible notes, current portion net of amortization	(443,212)	(887,042)
Note payable	22,076	
Total Current Liabilities	1,995,930	2,600,429
<b>LONG-TERM LIABILITIES</b>		
Convertible notes payable, net of current portion	1,000,000	653,375
Discount on convertible notes, net of current portion and amortization	(573,963)	(354,657)
Total Long-term Liabilities	426,037	298,718
<b>TOTAL LIABILITIES</b>	<b>2,421,967</b>	<b>2,899,147</b>
<b>COMMITMENTS, CONTINGENCIES AND SUBSEQUENT EVENTS</b>		
<b>STOCKHOLDERS EQUITY</b>		
Convertible Preferred Series A, \$.00067 Par Value, 50,000,000 and 25,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at June 30, 2008 and December 31, 2007.		
Common Stock, \$.00067 Par Value, 200,000,000 and 100,000,000 Shares Authorized, 40,592,247 and 39,980,611 Shares Issued, at June 30, 2008 and December 31, 2007, respectively	26,779	27,197
Additional Paid-In Capital	44,022,471	47,239,826

Edgar Filing: BIOLARGO, INC. - Form 10-Q

Accumulated Deficit	(35,013,283)	(39,088,753)
Total Stockholders' Equity	9,035,967	8,178,270
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 11,457,934</b>	<b>\$ 11,077,417</b>

See accompanying notes to consolidated financial statements

## BIOLARGO, INC. AND SUBSIDIARY

## CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE-AND SIX-MONTH PERIODS ENDED

JUNE 30, 2007 AND 2008

(unaudited)

	For the three-month periods ended June 30,		For the six-month periods ended June 30,	
	2007	2008	2007	2008
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Revenue	\$	\$	\$	\$
Total revenue				
Costs and expenses				
Selling, general and administrative	841,553	1,038,443	1,460,848	2,950,657
Research and development	23,511	43,961	42,003	93,684
Amortization	184,534	276,801	184,534	553,602
Total costs and expenses	1,049,598	1,359,205	1,687,385	3,597,943
Loss from operations	(1,049,598)	(1,359,205)	(1,687,385)	(3,597,943)
Other income and (expense)				
Interest expense	(141,619)	(302,686)	(1,194,820)	(493,211)
Other income	32,305	2,684	32,305	15,684
Net other income and (expense)	(109,314)	(300,002)	(1,162,515)	(477,527)
Net loss	\$ (1,159,912)	\$ (1,659,207)	\$ (2,849,900)	\$ (4,075,470)
Loss per common share basic and diluted				
Loss per share	\$ (0.04)	\$ (0.04)	\$ (0.16)	\$ (0.10)
Weighted average common share equivalents outstanding	30,777,550	40,531,284	17,631,060	40,161,737

See accompanying notes to consolidated financial statements

**BIOLARGO, INC. AND SUBSIDIARY****CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY****FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2008**

	Common Stock Number of Shares	Par Value \$.00067	Additional Paid-In Capital	Retained Earnings (Deficit)	Total
BALANCE DECEMBER 31, 2007	39,981,611	\$ 26,779	\$ 44,022,471	\$ (35,013,283)	\$ 9,035,967
Exercised warrants	487,000	334	608,416		608,750
Issuance of warrants as part of convertible note offering			601,898		601,898
Vested portion of stock options			953,769		953,769
Issuance of warrants to consultants			282,225		282,225
Issuance of stock options to Board of Directors and consultants			691,393		691,393
Conversion of convertible note payable obligations	124,636	84	79,654		79,738
Net loss for the six-month period ended June 30, 2008				(4,075,470)	(4,075,470)
BALANCE JUNE 30, 2008 (unaudited)	40,592,247	\$ 27,197	\$ 47,239,826	\$ (39,088,753)	\$ 8,178,270

See accompanying notes to consolidated financial statements

## BIOLARGO, INC. AND SUBSIDIARY

## CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX-MONTH PERIODS ENDED

JUNE 30, 2007 AND 2008

(unaudited)

	For the six-month periods ended	
	2007	2008
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net Loss	\$ (2,849,900)	\$ (4,075,470)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:		
Non-cash interest and additional non-cash expense related to conversion of noteholder obligations at below market price	1,216,904	
Conversion of consultant obligations and additional non cash expense	160,625	
Non-cash interest expense related to the fair value of warrants issued in conjunction with our convertible notes	219,316	382,110
Non-cash expense related to options issued to officers	158,961	690,109
Non-cash expense related to options issued to consultants		912,728
Non-cash expense related to warrants issued to consultants		282,225
Amortization of intangible assets	184,534	553,602
Decrease in prepaid expense	(16,500)	
Increase in accounts payable and accrued expenses	168,053	187,730
Net Cash Used In Operating Activities	(758,007)	(1,066,966)
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of fixed assets		(16,414)
Net Cash Used In Investing Activities		(16,414)
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from exercised warrants		608,750
Payments to note payable		(22,076)
Proceeds from convertible notes	613,000	653,375
Net Cash Provided By Financing Activities	613,000	1,240,049
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(145,007)	156,669
CASH AND CASH EQUIVALENTS BEGINNING	229,334	457,809
CASH AND CASH EQUIVALENTS ENDING	\$ 84,237	\$ 614,478
<b>SUPPLEMENTAL DISCLOSURES OF CASHFLOW INFORMATION</b>		
Cash Paid During the Period for:		
Interest	\$	\$
Income taxes	\$	\$
Conversion of note payable, related party to shares of the Company's common stock	\$ 900,000	\$
Conversion of convertible notes to shares of the Company's common stock	\$ 2,373,120	\$ 75,000
Conversion of accrued expenses to shares of the Company's common stock:		



Edgar Filing: BIOLARGO, INC. - Form 10-Q

Board of Directors and officer obligations	\$	608,759	\$
Consultant obligations	\$	740,296	\$
SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING AND INVESTING ACTIVITIES:			
Issuance of warrants in conjunction with convertible note offerings	\$	380,300	\$ 601,898
Issuance of shares of the Company's common stock in conjunction with the acquisition of assets from IOWC	\$	11,733,676	\$

See accompanying notes to consolidated financial statements

---

**BIOLARGO, INC. AND SUBSIDIARY**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**Note 1. Business and Organization**

**Outlook**

Prior to the acquisition of certain patented and patent-pending intellectual property and other assets (the BioLargo technology ) from IOWC Technologies, Inc. ( IOWC ) on April 30, 2007, BioLargo, Inc. (the Company , or we ) had no continuing business operations and operated as a shell company.

We will be required to raise substantial capital to sustain our expanded operations, including without limitation, hiring additional personnel, additional scientific and third-party testing, costs associated with obtaining regulatory approvals and filing additional patent applications to protect our intellectual property, and possible strategic acquisitions or alliances, as well as to meet our liabilities as they become due for the next 12 months.

We will need additional outside capital until and unless that technology is able to generate positive working capital sufficient to fund our cash flow requirements from operations.

These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. As reflected in the accompanying financial statements, we had a net loss of \$4,075,470 for the six-month period ended June 30, 2008, negative working capital of \$1,981,365 for the six-month period ended June 30, 2008, and negative cash flow from operating activities of \$1,066,966 for the six-month period ended June 30, 2008, and an accumulated stockholders deficit of \$39,088,753 as of June 30, 2008. Also, as of June 30, 2008, we had limited liquid and capital resources. The foregoing factors raise substantial doubt about our ability to continue as a going concern. Ultimately, our ability to continue as a going concern is dependent upon our ability to attract new sources of capital, exploit our technology so that it attains a reasonable threshold of operating efficiencies and achieves profitable operations. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Cash and cash equivalents totaled \$614,478 at June 30, 2008. We had no revenues in the quarter ended June 30, 2008, and financing activities primarily funded operations.

During the six-month period ended June 30, 2008, we sold an aggregate \$653,375 principal amount of our convertible promissory notes. This amount was sold pursuant to the offering commenced March 2008 due and payable March 31, 2010 to 25 investors. (See Note 3.)

During the six-month period ended June 30, 2008, we received \$608,750 from the exercise of our warrants. (See Note 4.)

As of June 30, 2008, we had \$2,578,375 aggregate principal amount, together with \$225,253 accrued and unpaid interest, outstanding on promissory notes that mature at various times during 2008, 2009 and 2010. (See Note 3.)

In the opinion of management, the accompanying balance sheets and related quarterly statements of operations, cash flows, and stockholders equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management s estimates and assumptions. Estimates are used when accounting for stock-based transactions, account payables and accrued expenses and taxes, among others.

Quarterly results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with Management s Discussion and Analysis and financial statements and notes thereto included in our annual report on Form 10-K for the year ended December 31, 2007.

## Organization

We were initially organized under the laws of the State of Florida in 1989 as Repossession Auction, Inc. In 1991, we merged into a Delaware corporation bearing the same name. In 1994, we changed our name to Latin American Casinos, Inc. to reflect our new focus on the gaming and casino business in South and Central America, and in 2001 we changed our name to NuWay Energy, Inc. to reflect our new emphasis on the oil and gas development industry. During October 2002, we changed our name to NuWay Medical, Inc. coincident with the divestiture of our non-medical assets and the retention of new management. In March 2007, in connection with the approval by our stockholders of the acquisition of the BioLargo technology, we changed our name to BioLargo, Inc.

## Intellectual Property

By leveraging our suite of patented and patent-pending intellectual property, which we refer to as the BioLargo technology, our business strategy is to harness and deliver nature's best disinfectant—iodine—in a safe, efficient, environmentally sensitive and cost-effective manner. Our BioLargo technology works by combining minerals with water from any source and delivering molecular iodine on demand, in controlled dosages, in order to balance efficacy of disinfectant performance with concerns about toxicity. When our BioLargo technology is incorporated in absorbent products, referred to as BI2O-SORB absorbents, third party testing has confirmed that the products also experience increased holding power and we believe that they may also experience increased absorption. Our BioLargo technology also includes know-how and trade secrets, which, together with our intellectual property, contribute to our expertise in product design, manufacturing, product claims, safety features and competitive positioning of products that feature our BioLargo technology.

Our BioLargo technology creates a value-added proposition to existing products and can be used to create new products. Our BioLargo technology can be incorporated into absorbents, washes and sprays, and into various products and applications across multiple industry verticals. Our BioLargo technology has the potential to replace other disinfectants such as chlorines and bromines, which may be harmful to the environment.

The centerpiece of our BioLargo technology is CupriDyne, a mineral and salt formulation that is the principal reactive agent we have focused on in our research and development, testing and patent protection to date and on which we will continue to devote substantial additional efforts. We have also engaged in research and development and, subject to adequate financing, intend to engage in additional research and development on, and testing and protection of, other formulations to deliver our BioLargo technology.

Our business model is to license our BioLargo technology to others, rather than to manufacture our own products. Our current focus is to develop opportunities to license our BioLargo technology to others in various vertical markets. We do not currently intend to manufacture our own products, although we will contract with others to manufacture the chemicals and minerals that comprise our BioLargo technology.

## Note 2. Intangible Assets/Long-lived Assets

Licensing rights are stated on the balance sheet net of accumulated amortization of \$1,192,464 as of June 30, 2008. Amortization expense for the six-month periods ended June 30, 2008 and 2007 was \$511,056 and \$170,352, respectively. At June 30, 2008 the weighted average remaining amortization period for the licensing rights was approximately 11 years.

Certain agreements assigned to us in connection with our acquisition of the BioLargo technology (the Assigned Agreements) are stated on the balance sheet net of accumulated amortization of \$99,274 at June 30, 2008. Amortization expense for the six-month periods ended June 30, 2008 and 2007 was \$42,546 and \$14,182, respectively. At June 30, 2008 the Assigned Agreements have a remaining amortization period of approximately 4 years.

### Note 3. Sale of Unregistered Securities

To fund our operations, we have raised money pursuant to several private offerings of our securities, the details of which are provided below.

#### 2008 Offering

In March 2008, we commenced a private offering (the 2008 Offering ) of up to \$1,000,000 of our 10% convertible promissory notes due March 31, 2010 ( 2010 Notes ). The 2008 Offering is subject to an over-allotment option of 15%, or a total of \$1,150,000 aggregate principal amount of 2010 Notes. The 2010 Notes are convertible into shares of our common stock at an initial conversion price of \$1.35 per share.

Each purchaser of the 2010 Notes will receive, for no additional consideration, two stock purchase warrants (collectively, the Warrants ), each of which entitles the holder to purchase a number of shares of our common stock into which the 2010 Note is convertible, the first warrant exercisable at an initial exercise price of \$1.50 per share and which expires on March 31, 2009 (the One-Year Warrants ), and the second warrant exercisable at an initial exercise price of \$2.00 per share and which expires on March 31, 2011 (the Three-Year Warrants ). (See Note 4.)

The 2010 Notes can be converted voluntarily by the noteholders at any time prior to the maturity date. We can unilaterally convert the 2010 Notes (i) on or after September 30, 2008, if we have received one or more written firm commitments, or have closed on one or more transactions, or a combination of the foregoing, of at least \$3 million gross proceeds of equity or debt; or (ii) on the maturity date. Accordingly, under such circumstances, the 2010 Notes may be repaid in cash or may be converted, at our sole option, into shares of our common stock, on the maturity date.

In the three-month period ended March 31, 2008, we did not receive any proceeds from the 2008 Offering. In the three-month period ended June 30, 2008, we received gross and net proceeds of \$653,375 and issued 2010 Notes, the principal amount of which allows for conversion into an aggregate 483,994 shares of our common stock.

#### 2007 Offering

Pursuant to a private offering that commenced in May 2007 (the 2007 Offering ) and terminated December 2007, we sold an aggregate \$1,000,000 of our convertible notes, which are due and payable on June 30, 2009 ( 2009 Notes ). Interest accrues at 10% compounding annually and is payable at our option in cash or stock at an initial conversion rate of \$0.70 per share. Purchasers of the 2009 Notes received, for no additional consideration, stock purchase warrants (the 2009 Warrants ) entitling the holder to purchase a number of shares of our common stock equal to the number of shares of common stock into which the principal amount of the investor's 2009 Note is convertible. The 2009 Warrants are exercisable at \$1.30 per share and will expire on June 30, 2010. (See Note 4.)

The 2009 Notes are convertible into shares of our common stock at an initial conversion price of \$0.70 per share. The 2009 Notes can be converted voluntarily by the noteholders at any time. We can unilaterally convert the 2009 Notes (i) on or after September 30, 2007, if we receive one or more written firm commitments, or have closed on one or more transactions, or a combination of the foregoing, of at least \$3 million gross proceeds of equity or debt; or (ii) on the maturity date. Accordingly, under such circumstances, the 2009 Notes may be repaid in cash or may be converted, at our sole option, into shares of our common stock, on the maturity date.

From the inception of the 2007 Offering in May 2007, through December 31, 2007, we received gross and net proceeds of \$1,000,000 and issued 2009 Notes, the principal amount of which allow for conversion into an aggregate 1,428,582 shares of our common stock.

The 2009 Notes have not been converted and remain outstanding, and are recorded on the June 30, 2008 balance sheet as convertible notes payable as current liabilities.

#### **Fall 2006 Offering**

In September 2006, we commenced a private offering that terminated in April 2007 (the Fall 2006 Offering). We sold an aggregate \$1,000,000 principal amount of our promissory notes (the Fall 2006 Notes) due and payable September 13, 2008 to 43 investors, the principal amount of which is convertible into 1,454,546 shares of our common stock. Of this amount, we sold an aggregate \$484,000 principal amount of Fall 2006 Notes as of December 31, 2006, and the \$516,000 during 2007. Each Fall 2006 Note bears interest at a rate of 10% per annum, such interest to be paid, at our option, in cash or stock at an initial conversion rate of \$0.6875 per share. Purchasers of the Fall 2006 Notes received, for no additional consideration, a stock purchase warrant (the Fall 2006 Warrant) entitling the holder to purchase a number of shares of our common stock into which the principal amount of the investor's Fall 2006 Note is convertible. The Fall 2006 Warrant is exercisable at an initial price of \$1.25 per share, and will expire on September 13, 2009. (See Note 4.)

The Fall 2006 Notes may be subordinated in an amount up to \$5 million of additional debt financing that we may incur prior to the maturity date. The Fall 2006 Notes are convertible into shares of our common stock at an initial conversion price of \$0.6875 per share. The Fall 2006 Notes can be converted voluntarily by the noteholders at any time prior to the maturity date. We can unilaterally convert the Fall 2006 Notes (i) on or after September 13, 2007, if we have received one or more written firm commitments, or have closed on one or more transactions, or a combination of the foregoing, of at least \$3 million gross proceeds of equity or debt; or (ii) on the maturity date. Accordingly, under such circumstances, the Fall 2006 Notes may be repaid in cash or may be converted, at our sole option, into shares of our common stock, on the maturity date.

From the inception of the Fall 2006 Offering in September 2006 through April 2007, we received gross and net proceeds of \$1,000,000 and issued 2006 Notes, the principal amount of which allow for conversion into an aggregate 1,454,564 shares of our common stock.

In May 2008, at the request of a holder of Fall 2006 Notes, we converted an aggregate principal amount of \$75,000 and \$10,687 of accrued but unpaid interest into an aggregate of 124,636 shares of our common stock, at a conversion rate of \$0.6875 per share. The remaining Fall 2006 Notes have not been converted and remain outstanding, and are recorded on the June 30, 2008 balance sheet as convertible notes payable as current liabilities.

All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(2) of the Securities Exchange Act and/or Regulation D promulgated thereunder as not involving a public offering of securities.

#### **Note 4. Warrants**

During the six-month period ended June 30, 2008, we issued warrants to purchase an aggregate 1,167,987 shares of our common stock. This included the following:

Purchasers of the 2010 Notes were issued two stock purchase warrants, each of which entitles the holder to purchase a number of shares of our common stock equal to the number of shares into which the principal amount of the related 2010 Note is convertible. We issued One-Year Warrants to purchase an aggregate 483,994 shares of our common stock. The One-Year Warrants are exercisable at an initial price of \$1.50 per share and will expire on March 31, 2009. Additionally, we issued Three-Year Warrants to purchase 483,994 shares of our common stock. The Three-Year Warrants are exercisable at an initial price of \$2.00 per share and will expire on March 31, 2011.

We also issued warrants to purchase 199,999 shares of our common stock to a consultant in exchange for services, pursuant to terms of the contract with the consultant, as follows: a warrant on January 31, 2008 to purchase 33,333 shares of common stock at \$1.00 per share; a warrant on January 31, 2008 to purchase 100,000 shares of common stock at \$1.50 per share; a warrant on February 29, 2008 to purchase 33,333 shares of common stock at \$1.58 per share; and a warrant on March 31, 2008 to purchase 33,333 shares of common stock at \$1.24 per share. These warrants vest immediately and expire ten years from the date of their respective issuance.

We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table:

	Number of Shares	Price Range
Outstanding as of December 31, 2007	5,292,682	\$ 0.125 1.50
Issued	1,141,875	\$ 1.00 2.00
Exercised	(487,000)	\$ 1.25
Expired	(1,276,200)	\$ 0.88 1.25
<b>Outstanding as of June 30, 2008</b>	<b>4,671,357</b>	<b>\$ 0.125 - 1.58</b>

To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option-pricing model and the calculated value is amortized over the life of the warrant. The determination of expense of warrants issued for services or settlement also uses the option-pricing model. The principal assumptions we used in applying this model were as follows:

	June 30, 2007	June 30, 2008
Risk free interest rate	4.52%	2.11 - 2.42%
Expected volatility	276 - 310 %	203 - 615%
Expected dividend yield		
Forfeiture rate		
Expected life in years	1.25 1.50	1 3.00

The risk-free interest rate is based on U.S Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.

The aggregate fair value of the warrants issued and outstanding as of June 30, 2008 totaled \$2,311,703. A total of \$340,478 was issued to consultants of which \$282,225 was expensed during the six-month period ended June 30, 2008 and the remaining \$58,253 was expensed during the year ended December 31, 2007. The remaining \$1,971,225 was issued in conjunction with our convertible notes and is recorded on our balance sheet as discount on convertible notes net of accumulated amortization of \$1,112,230. We recorded \$382,110 and \$219,316 of interest expense related to the amortization of the discount on convertible notes for the six-month periods ended June 30, 2008 and June 30, 2007, respectively.

During the six-month period ended June 30, 2008 we received an aggregate \$608,750 from the exercise of our warrants and issued 487,000 shares of our common stock at an exercise price of \$1.25 per share. During the six-month period ended June 30, 2008 warrants to purchase 1,276,200 shares of our common stock, at an exercise price of \$1.25, expired unexercised.

During 2007, we issued warrants to purchase an aggregate 2,179,128 shares of our common stock to investors as part of two private offerings, as follows. In connection with the Fall 2006 Offering we issued warrants to purchase 704,000 shares of our common stock. The warrants allow for the holders to purchase shares of our common stock at an exercise price of \$1.25 per share, and expire on September 13, 2009. In connection with the 2007 Offering, we issued warrants to purchase 1,428,582 shares of our common stock. The warrants allow for the holder to purchase shares of our common stock at an exercise price of \$1.30 per share, and expire June 30, 2010. (See Note 3.)

Also during 2007, in addition to warrants issued to investors, we issued warrants to purchase an aggregate 66,666 shares of our common stock to a consultant in exchange for services. The warrants allow the holder to purchase shares of our common stock at an exercise price of \$1.00 per share, are fully vested, and expire three years from the date of issuance. The fair value of these warrants was \$58,253 all of which was expensed during the year ended December 31, 2007.

## **Note 5. Stockholders Equity**

### **Preferred Stock**

Our certificate of incorporation authorizes our Board of Directors to issue preferred stock, from time to time, on such terms and conditions as they shall determine. As of June 30, 2008 and December 31, 2007 there were no outstanding shares of our preferred stock.

### **Common Stock**

As of June 30, 2008 and December 31, 2007 there were 40,592,247 and 39,980,611 shares of common stock outstanding, respectively. The increase in shares during the six-month period ended June 30, 2008 was due to (i) the issuance of 487,000 shares of our common stock in connection with the exercise of warrants (see Note 4), and (ii) the issuance of 124,636 shares of our common stock in connection with the conversion of a convertible note holder's principal and accrued and unpaid interest. (See Note 4.)

## **Note 6. Stock-Based Compensation and Other Employee Benefit Plans**

### **2007 Equity Incentive Plan**

On August 7, 2007, our Board of Directors adopted the BioLargo, Inc. 2007 Equity Incentive Plan ( 2007 Plan ) as a means of providing our directors, key employees and consultants additional incentive to provide services. Both stock options and stock grants may be made under this plan. The Compensation Committee administers this plan. The plan allows grants of common shares or options to purchase common shares. As plan administrator, the Compensation Committee has sole discretion to set the price of the options. The Compensation Committee may at any time amend or terminate the plan.

Under this plan, 6,000,000 shares of our common stock are reserved for issuance under awards. Any shares that are represented by awards under the 2007 Plan that are forfeited, expire, or are canceled or settled in cash without delivery of shares, or that are forfeited back to us or reacquired by us after delivery for any reason, or that are tendered to us or withheld to pay the exercise price or related tax withholding obligations in connection with any award under the 2007 Plan, will again be available for awards under the 2007 Plan. Only shares actually issued under the 2007 Plan will reduce the share reserve. If we acquire another entity through a merger or similar transaction and issue replacement awards under the 2007 Plan to employees, officers and directors of the acquired entity, those awards, to the extent permitted under applicable laws and securities exchange rules, will not reduce the number of shares reserved for the 2007 Plan.

The 2007 Plan imposes additional maximum limitations, which limitations will be adjusted to take into account stock splits, reverse stock splits and other similar occurrences. The maximum number of shares that may be issued in connection with incentive stock options granted to any one person in any calendar year intended to qualify under Internal Revenue Code Section 422 is 160,000 shares. The maximum number of shares that may be subject to stock options or stock appreciation rights granted to any one person in any calendar year is 200,000 shares, except that this limit is 400,000 shares if the grant is made in the year of the recipient's initial employment. The maximum number of shares that may be subject to restricted stock or restricted stock units granted to any one person in any calendar year is 200,000 shares. The maximum number shares that may be subject to awards granted to any one Participant in any calendar year of (i) performance shares, and/or performance units (the value of which is based on the Fair Market Value of a share of our common stock), is 200,000 shares; and (ii) of performance units (the value of which is not based on the Fair Market Value of a share of our common stock) that could result a payment of more than \$500,000.

During the six-month period ended June 30, 2008, we issued stock options to purchase 80,000 shares of our common stock to our Chief Financial Officer, pursuant to the terms of his consulting agreement, as follows: an option on February 1, 2008 to purchase 50,000 shares of common stock at \$1.89 per share; an option on April 30, 2008 to purchase 10,000 shares of common stock at \$1.65 per share; an option on May 31, 2008 to purchase 10,000 shares of common stock at \$1.55 per share; and an option on June 30, 2008 to purchase 10,000 shares of common stock at \$1.10 per share. The options vest immediately and expire ten years from the date of their respective issuance. The fair value of these options totals \$136,148, all of which was recorded as expense in the six-month period ended June 30, 2008. (See Note 10.)

On May 29, 2008, we granted options to purchase 10,000 shares of our common stock (each, a Director Option ) at an exercise price of \$1.45 per share to each of our independent directors pursuant to our 2007 Equity Incentive Plan. Each Director Option is exercisable for ten years and vests on the first anniversary of its date of grant. The fair value of the Director Options was \$28,388, all of which was expensed in the six-month period ended June 30, 2008.

During the six-month periods ended June 30, 2008 and 2007 we recorded an aggregate \$241,613 and \$0 in option compensation expense related to options issued pursuant to the 2007 Plan.

During the year ended December 31, 2007, we issued stock options under the 2007 Plan which allow for the purchase of an aggregate 625,000 shares of our common stock. The fair value of these options was an aggregate \$560,475. The options are exercisable at a price range of \$0.40 to \$1.03 and expire ten years from the grant date. Of this amount, \$98,015 was expensed during the year ended December 31, 2007. The remaining fair value of \$462,460 will be expensed ratably over the applicable vesting period. During the six-month periods ended June 30, 2008 and 2007, we recognized \$77,077 and \$0 compensation expense, respectively.



Edgar Filing: BIOLARGO, INC. - Form 10-Q

Activity for our stock options under the 2007 Plan for the six-month period ended June 30, 2008 is as follows:

	Options Outstanding	Shares Available	Price per share		Weighted Average Price per share
Balances, December 31, 2007	625,000	5,375,000	\$ 0.40	\$ 1.03	\$ 0.95
Granted	100,000	(100,000)	\$ 1.10 - 1.89		\$ 1.67
Exercised					
Canceled					
Balances, June 30, 2008	725,000	5,275,000	\$ 0.40	\$ 1.89	\$ 1.05

The following table summarizes the stock options issued under the 2007 Equity Plan outstanding at June 30, 2008.

Options Outstanding		Currently Exercisable				
Options						
Outstanding						
at June 30,	Exercise Price	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price	Number of Shares at June 30, 2008	Weighted Average Exercise Price	
2008						
20,000	\$ 0.40	10	\$ 0.40	20,000	\$ 0.40	
605,000	\$ 0.94 \$ 1.03	10	\$ 0.97	105,000	\$ 0.94	
50,000	\$ 1.89	10	\$ 1.89	50,000	\$ 1.89	
50,000	\$ 1.10 1.65	10	\$ 1.44	50,000	\$ 1.44	

**Stock Options issued outside the 2007 Equity Incentive Plan**

On January 10, 2008, pursuant to consulting agreements with Jeffrey C. Wallace and Robert J. Szolomayer, we issued options outside the 2007 Equity Plan to purchase 2,400,000 shares of our common stock at \$0.99 per share. Each option is exercisable for five years, and vests in four equal installments commencing on the date of the respective consulting agreement and continuing on each of December 31, 2008, December 31, 2009 and December 31, 2010 (each, an Option Vesting Date); provided that no additional portion of each option shall vest if Mr. Wallace or Mr. Szolomayer, as the case may be, is not providing services under his consulting agreement as of such Option Vesting Date. The fair value of these options was \$2,358,240 and for the six-month periods ended June 30, 2008 and 2007 we recognized \$884,340 and \$0 of consulting expense, respectively. (See Note 10.)

On April 30, 2007, we issued an option outside the 2007 Equity Plan to our Chief Executive Officer to purchase 7,733,259 shares of our common stock at \$0.18 per share, a discount to the \$0.37 closing price on the date of issuance. This option vests over three years in equal amounts on the anniversary date, and expires ten years from the date of issuance. The fair value of this option was \$2,861,306 and for the six-month periods ended June 30, 2008 and 2007 we recognized \$476,884 and \$158,961 of compensation expense, respectively.

We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Share-based compensation expense is based on the grant date fair value estimated in accordance with the provisions of SFAS 123R, using the Black-Scholes Option Pricing Model. The following methodology and assumptions were used to calculate share based compensation for the year ended June 30, 2008:

	Non plan Option		2007 Plan	
Risk free interest rate	2.17	4.50 %	2.72	4.52 %

Edgar Filing: BIOLARGO, INC. - Form 10-Q

Expected volatility	800%	800%
Expected dividend yield		
Forfeiture rate		
Expected life in years	5	5

Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

Following the guidance of Staff Accounting Bulletin No. 107, we follow the shortcut method to determine the expected term of plain vanilla options issued to employees and Directors. The expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.

The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future.

Stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, reduced for estimated forfeitures. SFAS 123R requires forfeitures to be estimated at the time of grant, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Historically, we have not had significant forfeitures of unvested stock options granted to employees and Directors. A significant number of our stock option grants are fully vested at issuance or have short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero.

#### Note 7. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses included the following:

	December 31, 2007	June 30, 2008
Accounts payable and accrued expenses	\$ 229,518	\$ 305,003
Accrued interest	493,860	606,911
Officer payable	57,843	19,037
Board of Director payable		38,000
<b>Total Accounts Payable and Accrued Expenses</b>	<b>\$ 781,221</b>	<b>\$ 968,951</b>

The accrued interest as of June 30, 2008, includes \$380,658 of accrued and unpaid interest related to a note held by New Millennium Capital Partners, LLC ( New Millennium ), which was not included in the conversion of the principal and which balance will remain outstanding and will not accrue additional interest (see Note 9). The remaining \$226,253 of accrued interest relates to the outstanding convertible notes. During the six-month periods ended June 30, 2008 and 2007, we recorded \$113,613 and \$77,240 of interest expense related to the convertible notes outstanding, respectively.

#### Note 8. Other Promissory Notes

On November 1, 2004, we converted \$25,000 of obligations owed to a former provider of professional services into a promissory note, which amount accrued interest at 5% per annum. As of September 1, 2007, we agreed to enter into a new loan agreement which converted the then accrued interest totaling \$5,000 to principal and entered into a new one year note totaling \$30,176, payable September 30, 2008 bearing interest at the rate of 6% per annum. We made certain progress payments in accordance with the terms of the new note and during the three-month period ended June 30, 2008 we fully satisfied the remaining balance due on the new note.

## **Note 9. Related Party Transactions**

### **New Millennium**

In March 2003, New Millennium Capital Partners, LLC ( *New Millennium* ), a company controlled by our president and chief executive officer, Dennis Calvert, purchased from a third party a promissory note in the principal amount of \$1,120,000 we assumed pursuant to a licensing transaction in October 2002.

On April 28, 2006, New Millennium agreed to amend the terms of the \$1,120,000 promissory note (the *New Millennium Note* ) to (i) extend the due date to January 15, 2008; (ii) waive any payments of interest until it becomes due; (iii) reduce the principal amount from \$1,120,000 to \$900,000, equal to a 19.6% reduction; and (iv) correspondingly reduce the accrued but unpaid interest due under the terms of the note from \$318,000 to \$256,000, also equal to a 19.6% reduction.

On April 13, 2007, we entered into an agreement with New Millennium whereby the \$900,000 principal amount of the *New Millennium Note* was converted into 1,636,364 shares of our common stock, at a price of \$0.55 per share, which was the last bid price on the date of conversion. The remaining accrued but unpaid interest in the amount of \$380,658 was not converted, and the parties agreed that no further interest would accrue, and that the interest would be paid on or before January 15, 2008. We are currently engaged in discussions with New Millennium to further extend the due date for payment of the accrued but unpaid interest.

## **Note 10. Commitments and Contingencies**

### **Litigation**

From time to time, we are party to various claims, legal actions and complaints arising periodically in the ordinary course of our business. In the opinion of management, no such matters will have a material adverse effect on our financial position or results of operations.

### **Attorney Fee Settlement**

In February 2008, we agreed to pay \$25,000, issue 15,000 shares of our common stock, and issue warrants to purchase an aggregate 15,000 shares of our common stock at \$1.50 per share, which warrants would expire three years from the date of issuance, in settlement of an account owed to a service provider. Since the date of the settlement, certain facts have come to light, and therefore, as of the date of this report on Form 10-Q, we have not issued the common stock or the warrants, but have recorded a \$42,050 expense in connection therewith.

### **Employment Agreements**

#### ***Joseph L. Provenzano Employment Agreement***

On January 10, 2008, we entered into an employment agreement with Joseph L. Provenzano (the *Provenzano Employment Agreement* ), pursuant to which Mr. Provenzano agreed to serve as Vice President of Operations effective January 1, 2008, in addition to continuing to serve as Corporate Secretary. The *Provenzano Employment Agreement* replaces a previous employment agreement dated March 1, 2003.

The *Provenzano Employment Agreements* provides that Mr. Provenzano will receive base compensation of \$79,200 annually (with automatic 10% annual increases). Mr. Provenzano is also entitled to reimbursement for authorized expenses he incurs in the course of his employment. In addition, Mr. Provenzano is eligible to receive discretionary bonuses, participate in benefits made generally available to our employees, and receive grants under our 2007 Equity Incentive Plan.

The initial term of the *Provenzano Employment Agreement* is one year and is automatically renewable for additional one-year periods unless we give at least 90 days notice of non-renewal. The *Provenzano Employment Agreement* also contains additional provisions typical of an agreement of this nature.

In connection with the execution of the Provenzano Employment Agreement, Mr. Provenzano also executed a non-disclosure agreement requiring him to keep certain information confidential, assigning to us creations and inventions during the term of his employment, and prohibiting him from soliciting business during the term of his employment and for a period of time thereafter.

***Engagement of Charles K. Dargan, II as Chief Financial Officer***

On February 1, 2008, we engaged Charles K. Dargan, II to serve as our Chief Financial Officer for a term of one year, subject to earlier termination on 30 days notice, and simultaneously Dennis P. Calvert resigned as our Chief Financial Officer. Mr. Calvert will continue to serve as our Chief Executive Officer, President and a director. During the term, Mr. Dargan will receive a fee of \$4,000 per month, which amount will be increased to \$8,000 or more in months during which we file our periodic reports with the Securities and Exchange Commission.

In addition to the cash compensation specified above, Mr. Dargan will be issued stock options over the term, as follows:

an option to purchase 50,000 shares of our common stock, granted on February 1, 2008, at an exercise price equal to the closing price of a share of our common stock on the grant date, such option to vest in full 90 days after grant; and

options to purchase 10,000 shares of our common stock, each such option to be granted on the last day of each month commencing April 2008 and ending January 2009, provided that this Agreement has not been terminated prior to each such grant date, at an exercise price equal to the closing price of a share of our common stock on each grant date, each such option to be fully vested upon grant.

Mr. Dargan will be reimbursed for business expenses he incurs in connection with the performance of his services as our Chief Financial Officer. The agreement with Mr. Dargan also contains provisions regarding indemnification and arbitration of disputes.

***Consulting Agreements***

Also on January 10, 2008, we entered into consulting agreements with each of Jeffrey C. Wallace (the Wallace Consulting Agreement) and Robert J. Szolomayer (individually the Szolomayer Consulting Agreement and collectively with the Wallace Consulting Agreement, the Consulting Agreements). Pursuant to the Wallace Consulting Agreement, Mr. Wallace has agreed to serve as our Director of Sales and Marketing effective January 1, 2008, and pursuant to the Szolomayer Consulting Agreement, Mr. Szolomayer has agreed to serve as our Director of Corporate Development effective January 1, 2008.

Other than referring to respective titles, the terms of the Consulting Agreements are identical. The Consulting Agreements provide that each of Messrs. Wallace and Szolomayer will receive (i) base compensation of \$90,000 annually, (ii) a share of a commission pool (the Commission Pool) to be established with respect to revenue it receives from third-parties evaluating, developing or licensing our BioLargo technology; and (iii) a stock purchase option (the Option). Each of Messrs. Wallace and Szolomayer is also entitled to reimbursement for authorized expenses he incurs in the course of his consultancy. The Commission Pool shall consist of an amount of money equal to a percentage of net licensing revenue (as defined in each Consulting Agreement), in the following amounts:

not less than 4% nor more than 7% of the Net Licensing Revenue actually and indefeasibly received by BioLargo in the first 12 months of the License Agreement Period for such License Agreement;

not less than 3% nor more than 5% of the Net Licensing Revenue actually and indefeasibly received by BioLargo in the second 12 months of the License Agreement Period for such License Agreement;

not less than 1% nor more than 3% of the Net Licensing Revenue actually and indefeasibly received by BioLargo in the third 12 months of the License Agreement Period for such License Agreement; and

not less than 0.75% nor more than 2% of the Net Licensing Revenue actually and indefeasibly received by BioLargo in the fourth 12 months and for each 12 month period thereafter, of the License Agreement Period for such License Agreement.

Each of Messrs. Wallace and Szolomayer shall be entitled to one-half (1/2) of the above-stated minimum amounts included in the Commission Pool during each calendar year during the term of the Consulting Agreements. Any and all of amounts in the Commission Pool which we may, in our sole and absolute discretion, contribute in excess of such above-stated minimum amounts up to the above-stated maximum amounts shall be paid to such persons, including either or both of Messrs. Wallace and Szolomayer, and in such amounts as we shall determine in its sole and absolute discretion. Pursuant to the Consulting Agreements, each of Messrs. Wallace and Szolomayer received an Option to purchase 1,200,000 shares of our common stock at \$0.99 per share. Each Option is exercisable for five years, and vests in four equal installments commencing on the date of the respective Consulting Agreement and continuing on each of December 31, 2008, December 31, 2009 and December 31, 2010 (each, an Option Vesting Date ); provided that no additional portion of each Option shall vest if Mr. Wallace or Mr. Szolomayer, as the case may be, is not providing services under his Consulting Agreement as of such Option Vesting Date. (See Note 6.)

The initial term of each of the Consulting Agreements is four years. Each of the Consulting Agreements also contains additional provisions typical of an agreement of this nature.

In connection with the execution of his respective Consulting Agreement, each of Messrs. Wallace and Szolomayer also executed a non-disclosure agreement requiring him to keep certain information confidential, assigning creations and inventions during the term of his consultancy and prohibiting him from soliciting business during the term of his consultancy and for a period of time thereafter.

#### **Stock-Based Commitments**

We have utilized the services of a number of consultants who have been compensated with shares of our common stock. While each agreement can generally be terminated with a 15-day notice, we may be obligated to issue additional shares to the consultants.

#### **Note 11. Subsequent Events**

Subsequent to the end of the six-month period ended June 30, 2008, we sold \$35,250 aggregate principal amount of notes, and issued One-Year Warrants to purchase an aggregate 26,112 shares of our common stock at an exercise price of \$1.50 and Three-Year Warrants to purchase an aggregate 26,112 shares of our common stock at an exercise price of \$2.00 per share, to a total of two investors.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

This Quarterly Report on Form 10-Q of BioLargo, Inc. (the Company) contains forward-looking statements. These forward-looking statements include predictions regarding, among other things, our:

our business plan;

the commercial viability of our technology and products incorporating our technology;

the effects of competitive factors on our technology and products incorporating our technology;

expenses we will incur in operating our business;

our liquidity and sufficiency of existing cash;

the success of our financing plans; and

the outcome of pending or threatened litigation.

You can identify these and other forward-looking statements by the use of words such as may, will, expects, anticipates, believes, estimates, continues, or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to any of the foregoing statements.

Such statements, which include statements concerning future revenue sources and concentrations, selling, general and administrative expenses, research and development expenses, capital resources, additional financings and additional losses, are subject to risks and uncertainties, including, but not limited to, those discussed elsewhere in this Form 10-Q, that could cause actual results to differ materially from those projected.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2007. Unless otherwise expressly stated herein, all statements, including forward-looking statements, set forth in this Form 10-Q are as of June 30, 2008, unless expressly stated otherwise, and we undertake no duty to update this information.

As used in this Report, the term Company refers to BioLargo, Inc., a Delaware corporation, and its wholly-owned subsidiary, BioLargo Life Technologies, Inc., a California corporation.

The following discussion and analysis should be read in conjunction with our unaudited consolidated financial statements and the related notes to the consolidated financial statements included elsewhere in this report.

**Overview**

By leveraging our suite of patented and patent-pending intellectual property, which we refer to as the BioLargo technology, our business strategy is to harness and deliver nature's best disinfectant iodine in a safe, efficient, environmentally sensitive and cost-effective manner. Our BioLargo technology works by combining minerals with water from any source and delivering molecular iodine on demand, in controlled dosages, in order to balance efficacy of disinfectant performance with concerns about toxicity. When our BioLargo technology is incorporated in absorbent products, referred to as BI<sub>2</sub>O-SORB absorbents, third party testing has confirmed that the products also experience increased holding power and we believe that they may also experience increased absorption. Our BioLargo technology also includes know-how and trade secrets, which, together with our intellectual property, contribute to our expertise in product design, manufacturing, product claims, safety features and competitive positioning of products that feature our BioLargo technology.

## Edgar Filing: BIOLARGO, INC. - Form 10-Q

Our BioLargo technology creates a value-added proposition to existing products and can be used to create new products. Our BioLargo technology can be incorporated into absorbents, washes and sprays, and into various products and applications across multiple industry verticals. Our BioLargo technology has the potential to replace other disinfectants such as chlorines and bromines, which may be harmful to the environment.



The centerpiece of our BioLargo technology is CupriDyne , a mineral and salt formulation that is the principal reactive agent we have focused on in our research and development, testing and patent protection to date and on which we will continue to devote substantial additional efforts. We have also engaged in research and development and, subject to adequate financing, intend to engage in additional research and development on, and testing and protection of, other formulations to deliver our BioLargo technology.

Our business model is to license our BioLargo technology to others, rather than to manufacture our own products. Our current focus is to develop opportunities to license our BioLargo technology to others in various vertical markets. We do not currently intend to manufacture our own products, although we will contract with others to manufacture the chemicals and minerals that comprise our BioLargo technology.

We operated as a shell company until the closing on April 30, 2007 of the acquisition of certain intellectual property and other assets from IOWC Technologies, Inc. ( IOWC ). Prior to such date, our operations primarily consisted of seeking funding, maintaining our corporate entity, complying with the reporting and other requirements of the Securities and Exchange Commission (the SEC ), engaging in ongoing research and development in cooperation with Mr. Kenneth R. Code for the BioLargo technology, engaging in initial marketing activities in cooperation with Mr. Code for the BioLargo technology and planning for the consummation of the acquisition of certain intellectual property and other assets from IOWC.

Since the completion of the acquisition from IOWC, we have focused on marketing our BioLargo technology to prospective licensees and negotiating contractual relationships with various potential licensees. In September and October of 2007, we entered into our first two commercial product testing and evaluation agreements, the efforts of which are continuing, with Johnson & Johnson Consumer and Personal Products Worldwide, and Syngenta Crop Protection, Inc.

We generated our first revenues in the third quarter of 2007. However, until full licensure of our BioLargo technology or the commercialization of products incorporating our BioLargo technology, our revenues will be uneven during the product testing, evaluation and development period. We did not generate any revenue in the quarter ended June 30, 2008 and, unless and until we are successful in negotiating and securing advance payments for licensing rights from prospective licensing candidates, we do not anticipate generating significant revenue during at least the remainder of 2008.

#### **Results of Operations Comparison of the Three- and Six-Month Periods Ended June 30, 2008 and 2007**

##### ***Revenue***

We generated no revenues from operations during the three- and six-month periods ended June 30, 2008 and 2007.

##### ***Selling, General and Administrative Expense***

Selling, General and Administrative expenses were \$1,038,443 and \$2,950,657 for the three- and six-month periods ended June 30, 2008, compared to \$841,553 and \$1,460,848 for the three- and six-month periods ended June 30, 2007, an increase of \$196,890 and \$1,489,809, respectively. The largest components of these expenses were:

a. Salaries and Payroll-related Expenses: These expenses were \$484,785 and \$948,669 for the three- and six-month periods ended June 30, 2008, compared to \$245,961 and \$302,161 for the three- and six-month periods ended June 30, 2007, an increase of \$238,824 and \$646,508, respectively. The increase is primarily attributable to stock option compensation expense. The remainder of the increase is attributable to salary compensation related to Kenneth R. Code, who became our Chief Technology Officer and a full-time employee in April 2007, and Charles K. Dargan II, who became our Chief Financial Officer in February 2008.

b. Consulting Expenses: These expenses were \$242,923 and \$1,367,748 for the three- and six-month periods ended June 30, 2008, compared \$101,376 and \$241,671 for the three- and six-month periods ended June 30, 2007, an increase of \$141,547 and \$1,126,077, respectively. The increase is primarily attributable to stock option expense related to the long-term consulting agreements with Robert Szolomayer, our Director of Corporate Development, and Jeffrey Wallace, our Director of Sales and Marketing, effective January 2008, and expenses related to the issuance of warrants to consultants and other professional advisors, partially offset by the change in status of Mr. Code from consultant to full-time employee in April 2007.

c. Professional Fees: These expenses were \$152,059 and \$354,492 for the three- and six-month periods ended June 30, 2008, compared to \$223,252 and \$511,196 for the three- and six-month periods ended June 30, 2007, a decrease of \$71,193 and \$156,704, respectively. The decrease is primarily attributable to the consummation of the acquisition of the BioLargo technology in April 2007, and the non-recurring nature of such expenses incurred in connection with that transaction.

#### ***Interest expense***

Interest expense totaled \$302,686 and \$493,211 for the three- and six-month periods ended June 30, 2008, compared to \$141,619 and \$1,194,820 for the three- and six-month periods ended June 30, 2007, an increase of \$161,067 and a decrease of \$701,609, respectively. The increase is primarily attributable to the interest expense recorded in connection with the amortization of the discount on convertible notes and the decrease is primarily attributable to the additional interest expense required to be recorded as the conversion price was below the stock price in connection with the March 2007 conversions of certain promissory notes to common stock.

#### ***Research and Development***

Research and development expenses were \$43,961 and \$93,684 for the three- and six-month periods ended June 30, 2008, compared to \$23,511 and \$42,003 for the three- and six-month periods ended June 30, 2007, an increase of \$20,450 and \$51,681, respectively. The increase is primarily attributable to increased activity related to further development work on our existing patents and patent applications.

#### ***Net Loss***

Net loss for the three- and six-month periods ended June 30, 2008 was \$1,659,207 and \$4,075,470, or a loss of \$0.04 and \$0.10 per share, compared to a net loss for the three- and six-month periods ended June 30, 2007 of \$1,159,278 and \$2,850,205, or a loss of \$0.04 and \$0.16 per share, respectively. The net loss in dollars increased due to the aforementioned increase in selling, general and administrative expenses, partially offset by the decrease in interest expense for the six-month period ended June 30, 2008. The net loss per share is the same in the three month periods ended June 30, 2008 and 2007 and declined in the six-month period ended June 30, 2008 compared to the six-month period ended June 30, 2007 because of the increase in the number of weighted average shares outstanding.

#### ***Liquidity and Capital Resources***

We have been, and anticipate that we will continue to be, limited in terms of our capital resources. We generated no revenues in the six-month period ended June 30, 2008. Cash and cash equivalents totaled \$614,478 at June 30, 2008. We had negative working capital of \$1,981,365 for the six-month period ended June 30, 2008, and negative cash flow from operating activities of \$1,066,966 compared to a negative cash flow from operating activities of \$758,007 for the six-month periods ended June 30, 2008 and 2007, respectively. Therefore, we were compelled to use cash from financing activities to fund operations. Our cash position is insufficient to meet our continuing anticipated expenses or fund anticipated operating expenses. Accordingly, we will be required to raise significant additional capital to sustain operations and further implement our business plan.

The financial statements accompanying this report have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. As reflected in the accompanying financial statements, we had a net loss of \$4,075,470 for the six-month period ended June 30, 2008, and a stockholders' deficit of \$39,088,753 as of June 30, 2008. The foregoing factors raise substantial doubt about our ability to continue as

a going concern. Ultimately, our ability to continue as a going concern is dependent upon its ability to attract new sources of capital, attain a reasonable threshold of operating efficiencies and achieve profitable operations by commercializing products incorporating our BioLargo technology. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

As of June 30, 2008 we had \$2,578,375 principal amount, together with \$226,253 accrued and unpaid interest, outstanding on various promissory notes. We may pay all of this amount in cash or in stock, at our option, at maturity. In addition, as of June 30, 2008, we had \$362,040 in accrued and unpaid payables and \$386,658 in accrued and unpaid interest to New Millennium Capital Partners, LLC, an entity controlled by Dennis Calvert, our President and Chief Executive Officer.

To provide additional working capital, we commenced a private offering of up to \$1,000,000 of our 10% convertible promissory notes due March 31, 2010. As of June 30, 2008, we raised \$653,375 gross and net proceeds, and subsequent to June 30, 2008, we raised an additional \$35,250 gross and net proceeds. The offering is continuing. See Part II, Item 2, Unregistered Sales of Equity Securities and Use of Proceeds and Notes 3 and 11 to Notes to Financial Statements .

We estimate that our current cash, including the net proceeds we have received thus far in the ongoing offering, will provide sufficient capital to meet operating expenses and other financial obligations, assuming that we undertake no new projects or incur no new obligations, only through October 2008. We will be required to raise substantial additional capital to sustain our expanded operations, including without limitation, hiring additional personnel, additional scientific and third-party testing, costs associated with obtaining regulatory approvals and filing additional patent applications to protect our intellectual property, and possible strategic acquisitions or alliances, as well as to meet our liabilities as they become due for the next 12 months.

If we are unable to raise sufficient capital, we may be required to curtail some of our operations, including efforts to develop, test, market, evaluate and license our BioLargo technology. If we were forced to curtail aspects of our operations, there could be a material adverse impact on our financial condition and results of operations.

In addition to the ongoing private offering discussed above, we are also actively pursuing numerous alternatives for our current and longer-term financial requirements, including additional raises of capital from investors in the form of convertible debt or equity. We have retained the services of Taglich Brothers, Inc. of New York to serve as our exclusive financial advisor. However, there can be no assurance that we will be able to raise any additional capital. It is also unlikely that we will be able to qualify for bank or other financial institutional debt financing until such time as our operations are considerably more advanced and we are able to demonstrate the financial strength to provide confidence for a lender, which we do not currently believe is likely to occur for at least the next 12 months or more.

#### **Critical Accounting Policies**

Our discussion and analysis of our results of operations and liquidity and capital resources are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, valuation of intangible assets and investments, and share-based payments. We base our estimates on anticipated results and trends and on various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results that differ from our estimates could have a significant adverse effect on our operating results and financial position. We believe that the following significant accounting policies and assumptions may involve a higher degree of judgment and complexity than others.

The methods, estimates and judgments the Company uses in applying these most critical accounting policies have a significant impact on the results of the Company reports in its financial statements.

We anticipate that any generated revenue will principally be derived from royalties and license fees from our intellectual property. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using our licensed intellectual property. License fees are recognized over the estimated period of future benefit to the average licensee.

The Company has established a policy relative to the methodology to determine the value assigned to each intangible acquired with or licensed by the Company and/or services or products received for non-cash consideration of the Company's common stock. The value is based on the market price of the Company's common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received, as adjusted for applicable discounts.

It the Company's policy to expense share based payments as of the date of grant in accordance with Financial Accounting Standards Board Statement No. 123R Share-Based Payment. Application of this pronouncement requires significant judgment regarding the assumptions used in the selected option pricing model, including stock price volatility and employee exercise behavior. Most of these inputs are either highly dependent on the current economic environment at the date of grant or forward-looking expectations projected over the expected term of the award. As a result, the actual impact of adoption on future earnings could differ significantly from our current estimate.

### **Recent Accounting Pronouncements**

In December 2007, the Financial Accounting Standards Board ( FASB ) issued SFAS No. 141 (revised 2007), *Business Combinations* ( SFAS No. 141R ), which revises current purchase accounting guidance in SFAS No. 141, *Business Combinations*. SFAS No. 141R requires most assets acquired and liabilities assumed in a business combination to be measured at their fair values as of the date of acquisition. SFAS No. 141R also modifies the initial measurement and subsequent re-measurement of contingent consideration and acquired contingencies, and requires that acquisition related costs be recognized as expense as incurred rather than capitalized as part of the cost of the acquisition. SFAS No. 141R is effective for fiscal years beginning after December 15, 2008 and is to be applied prospectively to business combinations occurring after adoption. The impact of SFAS No. 141R on the Company's consolidated financial statements will depend on the nature and extent of the Company's future acquisition activities.

In February 2007, the FASB issued Statement No. 159, *The Fair Value Option for Financial Assets and Liabilities* ( SFAS No. 159 ). This Statement permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. The fair value option established by SFAS No. 159 permits all entities to choose to measure eligible items at fair value at specified election dates. A business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings (or another performance indicator if the business entity does not report earnings) at each subsequent reporting date. SFAS No. 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. We do not believe that the adoption of SFAS No. 159 will have a material affect on our financial statements.

In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements* ( SFAS No. 157 ), which establishes a standard definition for fair value, provides a framework under generally accepted accounting principles for measuring fair value, and expands disclosure requirements for fair value measurements. FASB Staff Position No. FAS 157-b, *Effective Date of FASB No 157*, issued in December 2007, delays the effective date of SFAS No. 157 to annual reporting periods beginning after November 15, 2008 for all non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. The remaining provisions of SFAS No. 157 are effective for annual reporting periods beginning after November 15, 2007. The adoption of SFAS No. 157 may require increased disclosures in the Company's consolidated financial statements.

Other recent accounting pronouncements issued by FASB (including its Emerging Issued Task Force), the American Institute of Certified Public Accountants and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Not applicable.

**Item 4T. Controls and Procedures**

(a) *Evaluation of disclosure controls and procedures.* We conducted an evaluation, under the supervision and with the participation of Dennis P. Calvert, our Chief Executive Officer and Charles K. Dargan II, our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report.

Based on this evaluation, our chief executive officer and chief financial officer concluded that as of the evaluation date our disclosure controls and procedures were generally effective. Our procedures have been designed to ensure that the information relating to our company, including our consolidated subsidiary, required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure.

Nonetheless, we believe that further steps are warranted to better assure the effectiveness of these disclosure controls and procedures. We have implemented certain steps in furtherance of this objective and believe, subject to our continuing evaluation and review of these further steps, that additional steps may be warranted. In February 2008, we hired a Chief Financial Officer who is a Certified Public Accountant. Additional steps that the Company believes it must undertake are to retain a consulting firm to, among other things, design and implement adequate systems of accounting and financial statement disclosure controls during the current fiscal year to comply with the requirements of the SEC. We believe that the ultimate success of our plan to improve our internal controls over financial reporting and disclosure controls and procedures will require a combination of additional financial resources, outside consulting services, legal advice, additional personnel, further reallocation of responsibility among various persons, and substantial additional training of those of our officers, personnel and others, including certain of our directors such as our committee chairs, who are charged with implementing and/or carrying out our plan.

It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

(b) *Changes in internal control over financial reporting.* There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**PART II**

**Item 1. Legal Proceedings**

From time to time, we are party to various claims, legal actions and complaints arising periodically in the ordinary course of our business. In the opinion of management, no such matters will have a material adverse effect on our financial position or results of operations.

**Item 1A. Risk Factors**

No change.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

On May 15, 2008, a holder of two convertible promissory notes in the aggregate principal amount of \$75,000 voluntarily converted the notes, together with accrued and unpaid interest in the amount of \$10,687, into 124,636 shares of our common stock, at a rate of \$0.6875 per share in accordance with the terms of such notes. We did not receive any proceeds in connection with this conversion.

In March 2008, we commenced a private offering of up to \$1,000,000 of our 10% convertible promissory notes due March 31, 2010 ( 2010 Notes ). The offering is subject to an over-allotment option of 15%, or a total of \$1,150,000 aggregate principal amount of 2010 Notes. The 2010 Notes are convertible into shares of our common stock at an initial conversion price of \$1.35 per share. Each purchaser of the 2010 Notes will receive, for no additional consideration, two stock purchase warrants, each of which entitles the holder to purchase a number of shares of our common stock into which the 2010 Note is convertible, the first warrant exercisable at an initial exercise price of \$1.50 per share and which expires on March 31, 2009 (the One-Year Warrants ), and the second warrant exercisable at an initial exercise price of \$2.00 per share and which expires on March 31, 2011 (the Three-Year Warrants ).

In the three-month period ended June 30, 2008, we sold \$653,375 aggregate principal amount of 2010 Notes, and issued One-Year Warrants to purchase an aggregate 483,994 shares of our common stock at an exercise price of \$1.50 and Three-Year Warrants to purchase an aggregate 483,994 shares of our common stock at an exercise price of \$2.00 per share, to a total of 25 investors.

During the three-month period ended June 30, 2008, we granted options to purchase shares of our common stock at the rate of 10,000 shares per month, or a total of 30,000 shares, to our chief financial officer, pursuant to the terms of our consulting agreement with him. These options are exercisable at various exercise prices ranging between \$1.10 and \$1.65 depending upon their respective dates of grant. Each option is fully vested upon grant and is exercisable for ten years from its respective date of grant.

On May 29, 2008, we granted options to purchase 10,000 shares of our common stock (each, a Director Option ) at an exercise price of \$1.45 per share to each of our independent directors pursuant to our 2007 Equity Incentive Plan. Each Director Option is exercisable for ten years and vests on the first anniversary of its date of grant.

All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(2) of the Securities Exchange Act and/or Regulation D promulgated thereunder as not involving a public offering of securities.

**Item 3. Defaults Upon Senior Securities**

None

**Item 4. Submission of Matters to a Vote of Security Holders**

Stockholders beneficially owning 26,492,907 shares, or approximately 65.5%, of our outstanding common stock as of April 25, 2008, executed a written consent as of May 29, 2008, with respect to the election of the following five directors to serve until our 2009 annual meeting of stockholders or until each such person's successor is duly elected and qualified:

Name	For	Withheld
Dennis P. Calvert	26,492,907	(1)
Kenneth R. Code	26,492,907	(1)
Gary A. Cox	26,492,907	(1)
Dennis E. Marshall	26,492,907	(1)
Joseph L. Provenzano	26,492,907	(1)

(1) Because proxies were not solicited, withheld votes cannot be calculated.

**Item 5. Other Information**

None

**Item 6. Exhibits**

The exhibits listed below are attached hereto and filed herewith:

Exhibit No.	Description
31.1	Certification of Chief Executive Officer of Quarterly Report Pursuant to Rule 13(a)-15(e) or Rule 15(d)-15(e).
31.2	Certification of Chief Financial Officer of Quarterly Report Pursuant to 18 U.S.C. Section 1350
32	Certification of Chief Executive Officer and Chief Financial Officer of Quarterly Report pursuant to Rule 13(a)-15(e) or Rule 15(d)-15(e).

**SIGNATURES**

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant has caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

BIOLARGO, INC.

Date: August 14, 2008

By: /s/ DENNIS P. CALVERT  
Dennis P. Calvert  
Chief Executive Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
31.1	Certification of Chief Executive Officer of Quarterly Report Pursuant to Rule 13(a)-15(e) or Rule 15(d)-15(e).
31.2	Certification of Chief Financial Officer of Quarterly Report Pursuant to 18 U.S.C. Section 1350
32	Certification of Chief Executive Officer and Chief Financial Officer of Quarterly Report pursuant to Rule 13(a)-15(e) or Rule 15(d)-15(e).